Rare Biomarkers Specimen Collection and Stabilization: Global Strategic Business Report

Global Rare Biomarkers Specimen Collection and Stabilization Market to Reach $59 Billion by 2027

In the changed post COVID-19 business landscape, the global market for Rare Biomarkers Specimen Collection and Stabilization estimated at US$32 Billion in the year 2020, is projected to reach a revised size of US$59 Billion by 2027, growing at a CAGR of 9.2% over the analysis period 2020-2027. Circulating Cell Free DNA (ccfDNA), one of the segments analyzed in the report, is projected to record a 8.5% CAGR and reach US$23.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Circulating Tumor Cells (CTCs) segment is readjusted to a revised 9.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $9.5 Billion, While China is Forecast to Grow at 8.6% CAGR

The Rare Biomarkers Specimen Collection and Stabilization market in the U.S. is estimated at US$9.5 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$10.3 Billion by the year 2027 trailing a CAGR of 8.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 7.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Exosomes / Extracellular Vesicles Segment to Record 10.3% CAGR

In the global Exosomes / Extracellular Vesicles segment, USA, Canada, Japan, China and Europe will drive the 10.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$4.2 Billion in the year 2020 will reach a projected size of US$8.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 32 Featured) -

• Advanced Cell Diagnostics, Inc.
• Agena Bioscience
• ANGLE plc
• ApoCell, Inc.
• AS One InternationalNTERNATIONAL
• BioChain Institute, Inc.
• Biolidics Limited
• Biomatrica
• Bio-Techne Corporation
• BioVision, Inc.
• Caltag Medsystems Limited
• Cytomark Ltd.
• DNA Genotek, Inc.
• Epic Sciences
• EpiGentek Group Inc.
• F. Hoffmann-La Roche Ltd
• Fluxion Biosciences, Inc.
• Geno Technology Inc.
• Genomax Technologies Pte Ltd.
• GILUPI GmbH
• LifeSpan BioSciences, Inc.
• MagBio Genomics Inc.
• Menarini Silicon Biosystems
• MyBioSource.com
• Norgen Biotek Corp.
• Novus Biologicals, LLC
• OraSure Technologies Inc.
• Precision for Medicine, Inc.
• Promega Corporation
• QIAGEN
• Rarecells Diagnostics SAS
• RareCyte, Inc.
• siemens Healthineers
• SiO2 Materials Science
• STEMCELL Technologies Inc.
• Streck, Inc.
• Thermo Fisher Scientific, Inc.
• Vortex Biosciences
• VyCAP B.V.

What's New for 2022?

• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year